ArticleBMJ open2024

Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA.

Biao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.